scholarly journals Trends and Indications of Hematopoietic Stem Cell Transplantation in Pediatric Population below Two Year Old: Insight from Nationwide Inpatient Sample

2019 ◽  
Vol 25 (3) ◽  
pp. S317
Author(s):  
Eman M. Elsabbagh ◽  
Ahmed Elkaryoni
2015 ◽  
Vol 37 (4) ◽  
pp. 236-241 ◽  
Author(s):  
Daniela Hespanha Marinho ◽  
José Zanis Neto ◽  
Carmem Maria Sales Bonfim ◽  
Vaneuza Araujo Moreira Funke ◽  
Lisandro Lima Ribeiro

2005 ◽  
Vol 93 (04) ◽  
pp. 682-689 ◽  
Author(s):  
Luca Spiezia ◽  
Simone Cesaro ◽  
Chiara Messina ◽  
Myriam Paris ◽  
Marta Pillon ◽  
...  

SummaryHepatic veno-occlusive disease (VOD) is a severe complication after hematopoietic stem cell transplantation (HSCT). Recent studies, mainly in adults receiving HSCT, have identified an increase in the plasminogen activator inhibitor-1 (PAI-1) as a possible marker of VOD. To confirm this finding, the fibrinolytic, coagulation and liver function parameters were assayed before and weekly for 1 month after 61 HSCT performed in 53 consecutive children. Non-VOD patients had a slight increase in t-PA antigen, fibrinogen and P-selectin levels, as well as a mildly longer aPTT and a drop in antithrombin after HSCT. The 6 children with VOD (9.84%) had an early and significant increase in PAI-1 antigen and activity (p< 0.0001), t-PA antigen (p< 0.0001) and D-dimer (p< 0.01) levels, and a decrease in plasminogen, α2-antiplasmin and PT emerged 2(±1) days before the clinical diagnosis of VOD by comparison with mean post-HSCT values in the non-VOD patients. Significant differences were also detected for these parameters and antithrombin levels between non-VOD and VOD patients soon after the clinical onset of VOD, whereas the rise in bilirubin levels became significant only later on. In conclusion, variations in fibrinolytic test findings after HSCT, and PAI-1 in particular, may facilitate the early diagnosis of VOD in pediatric patients after HSCT.


2016 ◽  
Vol 34 (1) ◽  
pp. 13-19 ◽  
Author(s):  
Pablo Pérez-Huertas ◽  
Margarita Cueto-Sola ◽  
Paloma Escobar-Cava ◽  
José María Fernández-Navarro ◽  
Carmela Borrell-García ◽  
...  

Objective: To study the incidence, risk factors, and treatment of hemorrhagic cystitis secondary to BK-virus reactivation (HC-BKV) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the pediatric population. Methods: Case-control study in which all pediatric patients (0-18 years) who underwent allo-HSCT from September 2009 to January 2014 were followed. Results: Twenty-nine patients underwent an allo-HSCT. The median age was 9 years (range = 6 months to 15 years), 61% male. The primary diagnosis was acute lymphoblastic leukemia (72.4%). Six (20.7%) developed HC-BKV. In a multivariate analysis of risk factors, it was observed that the reactivation of BK virus was associated with age more than 10 years ( P = .098) and those with positive serology for Epstein-Barr virus ( P = .06). Five of the 6 patients with HC-BKV received cidofovir (CDV) at doses of 3 to 5 mg/kg/week. The treatment lasted a median of 3 cycles (range = 2-5). One of the patients (20%) developed nephrotoxicity. Of the 5 patients treated with CDV, 3 (60%) had a complete response, 1 (20%) partial response, and 1 (20%) no response. Conclusion: We conclude that HC-BKV is a frequent complication after allo-HSCT. CDV therapy can be effective but controlled clinical trials are needed.


2020 ◽  
Vol 8 (1) ◽  
pp. 67-78 ◽  
Author(s):  
Anne E. Kazak ◽  
Avi Madan Swain ◽  
Ahna L. H. Pai ◽  
Kimberly Canter ◽  
Olivia Carlson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document